Tag Archives: PRAME

Afami-cel BLA Submission on Track for YE 2023, Lete-cel IND Set to Transition from GSK by YE 2023; MSLN TRuC Programs Deprioritized; Adaptimmune to Advance PRAME Program to the Clinic in 2024; Adaptimmune’s Q3 2023 Earnings Call

On Wednesday, November 8, Adaptimmune held its Q3 2023 earnings call (press release / webcast), confirming that completion of the BLA submission for afami-cel (MAGE-A4 SPEAR-T) is still on track for Q4 2023 while highlighting that the transition of lete-cel (NY-ESO-1 TCR-T) IND from GSK is expected to be closed by YE 2023. Moreover, management anticipated updated milestones for its pipeline assets, including deprioritizing two clinical programs and the selection of a PRAME candidate for clinical development. Below, Celltelligence provides insights on afami-cel potential approval, while discussing Adaptimmune’s pipeline re-prioritization strategy.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Strategic Merger of Adaptimmune and TCR2 Tx; Afami-cel’s BLA Filing Completion on Track for Mid-2023; Progress in ADP-A2M4CD8’s Clinical Development; Adaptimmune Q4 2022 Earnings Call Summary

On Monday, March 6, Adaptimmune held its Q4 and FY 2022 earnings call (press release / presentation) highlighting an agreement with TCR2 Tx for merging into a preeminent cell therapy company focused on treating solid tumors (press release). Additionally, management presented updates from afami-cel’s (autologous MAGE-A4 SPEAR-T) BLA filing in synovial sarcoma and ADP-A2M4CD8’s (autologous MAGE-A4 TCR-T) Ph2 SURPASS-3 trial in ovarian cancer. Below, Celltelligence provides insights on the decision of Adaptimmune to partner with TCR2 Tx while discussing the potential of their combined pipeline in the treatment of solid tumors.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Afami-cel’s Rolling BLA Submission to Initiate in Q4 2022; Adaptimmune Prioritizes MAGE-A4 and PRAME Assets; No Major Updates for Gavo-cel and TC-510; Adaptimmune and TCR2 Tx Q3 2022 Earnings Summaries

On Tuesday, November 8, 2022, Adaptimmune held its Q3 2022 earning call (press release) highlighting that afami-cel’s (MAGE-A4 SPEAR-T) rolling BLA submission for synovial sarcoma will initiate in Q4 2022. Additionally, management announced that they will focus exclusively on MAGE-A4 and PRAME assets, while deprioritizing or pausing the development of non-core programs. On the same day, TCR2 Tx reported its Q3 2022 financials and business updates (press release) highlighting positive topline results from gavo-cel’s (TC-210; autologous mesothelin TRuC-T) Ph1/2 trial in mesothelin-expressing solid tumors. Below, Celltelligence provides insights on Adaptimmune’s pipeline prioritization strategy after GSK’s transfer of assets, while discussing potential delays in TCR2 Tx’s programs.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Latest Advances Targeting Neoantigens and Developing TCR-T Cell Therapies; Ziopharm Presents Preclinical Data from Their Hotspot TCR-T Library Program; Medigene’s PRAME-Specific TCR PD1-41BB Switch Receptor Could Treat a Broad Range of Liquid and Solid Tumors; AACR 2021 Day 6

On the final day of AACR 2021 Week I, two key TCR-T platform updates were presented from Ziopharm and Medigene, while different approaches for neoantigen discovery and TCR evaluation were explored in a panel discussion. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.